CYH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CYH is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has a mild short-term bounce setup, but the broader trend is still weak, analyst sentiment is only Hold/Neutral with lower price targets, and the latest quarter showed declining revenue and continued losses. With no AI Stock Picker or SwingMax buy signal, this is better treated as a hold/watch than an immediate buy.
Current price is 2.90, basically flat versus the prior close, with only a modest regular-session gain and a slight pre-market dip. MACD histogram is positive and expanding, which supports near-term momentum improvement, but RSI at 52.7 is neutral and does not signal strong upside. The moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer-term trend is still down. Key levels are Pivot 2.753, resistance at 2.98 and 3.121, and support at 2.526 and 2.385. Overall, the chart suggests short-term stabilization inside a still-bearish longer-term structure.
["MACD histogram is positive and expanding, suggesting improving near-term momentum.", "Price is holding above the pivot level at 2.753, which may support a short-term base.", "No negative news was reported in the last week, so there is no fresh event-driven pressure.", "Analyst expectations still point to some long-run sector support from defensive healthcare demand, according to prior commentary."]
["Q1 revenue fell 6.14% YoY, showing weaker top-line growth.", "The company remains unprofitable, with net income at -58M and EPS at -0.43.", "Analysts recently cut price targets to $3.00 and kept only Hold/Equal Weight ratings after the Q1 miss.", "Management-guided low single-digit growth is not strong enough to support a high-conviction long-term buy.", "Longer-term technical trend is bearish with SMA_200 above shorter averages.", "No recent news catalysts, no significant insider buying/selling, and no recent congress trading data to support a bullish thesis."]
Latest quarter: 2026/Q1. Revenue decreased to 2.965B, down 6.14% YoY, which is a negative growth signal. Net income was still negative at -58M, though improved sharply versus last year, and EPS improved to -0.43 but remains below zero. Gross margin was high at 81.28% and slightly improved, which is a positive, but overall the quarter still shows declining sales and continued losses rather than a clean turnaround.
Recent analyst trend is negative-to-neutral. Truist lowered its target to $3 from $3.50 and kept Hold after Q1, citing EBITDA below consensus and softer volumes. Barclays also cut its target to $3 from $3.50 and kept Equal Weight, pointing to soft volumes and surgical activity. Earlier, UBS had raised its target slightly to $3.70 and stayed Neutral. Wall Street’s pros view: defensive healthcare exposure and potential sector support. Cons view: weak quarter, lower targets, and no strong bullish ratings shift. No recent politician or influential figure trading activity was reported, and no recent congress trading data was available.
